Clinical trial NCT03370874: Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.
Official title: Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetic Foot Ulcer
Lead sponsor: Anterogen Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-12-13
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to placebo therapy.

Detailed description: Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional, Study design: Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study

Eligibility criteria: Inclusion Criteria:

1. Subject is between 18 and 75 years of age.
2. Subject is diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer than 4 weeks at the screening visit.
3. Foot ulcer size is between 1 cm2 and 15 cm2
4. Ulcer graded I or II by Wagner grade, and extended to skin, tendon, and subcutaneous tissue.
5. Free of necrotic debris at target ulcer
6. Around ulcer area blood circulation should be secured to meet one of below criteria;

   * Blood vessels around the ulcer detected by Doppler Test
   * 0.7 \< Ankle Brachial Index(ABI) \< 1.3
   * Transcutaneous Oxygen Pressure, TcPO2 higher than 30 mmHg
7. Subject is able to give written informed consent prior to study start and to comply with the study requirements during study.

Exclusion Criteria:

1. Non-diabetic pathophysiologic ulcer.
2. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.
3. Subjects requiring intravenous (IV) antibiotics to treat infection.
4. Current evidence of infection including pus drainage from the wound site.
5. Subject has a glycated hemoglobin A1c (HbA1c) level of \> 15%
6. Subject's blood sugar is \> 450 mg/dl at postprandial.
7. Subjects with severe renal failure that cannot be managed by renal dialysis.
8. Subjects with severe hepatic deficiencies.
9. Subject is Human Immunodeficiency Virus (HIV) positive.
10. Subject who has allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.
11. Subject who is pregnant or breast-feeding.
12. Subjects who are unwilling to use an "effective" method of contraception during the study.
13. Subjects who have a clinically relevant history of alcohol or drugs abuse.
14. Subjects who are not able to understand the objective of this study or to comply with the study requirements.
15. Subjects who are considered to have a significant disease which can impact the study by investigator.
16. Subjects who are considered not suitable for the study by investigator.
17. Subjects who had had a history of surgery for malignant tumor within the last five years (except carcinoma in situ).
18. Subjects who are currently or are enrolled in another clinical study within 60 days of screening.
19. Subjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.
20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.
21. Subjects not comply with off-loading procedure

Primary outcomes:
measure: Proportions of subjects who achieved complete wound closure
timeFrame: During 12 weeks
Secondary outcomes:
measure: Time taken to complete wound closure between the two groups
timeFrame: During 12 weeks
measure: Proportions of subjects who achieved complete wound closure
timeFrame: Follow up to 12 weeks
measure: Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups
timeFrame: Follow up to 12 weeks
measure: Change rates in wound size and depth compared to baseline between the two groups
timeFrame: During 12 weeks
measure: Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations
timeFrame: Follow up to 12 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Kuro Hospital
Study officials:
affiliation: Korea University Guro Hospital
name: Seung-Kyu Han, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Eulji General Hospital
name: Ki-Won Young, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: Junpyo Hong, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Konkuk University Medical Center
name: Donghyeok Shin, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Keimyung University Dongsan Medical Center
name: Junhyeong Kim, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Chungnam National University Hospital
name: Kang Chan, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Ajou University Medical Center
name: Hyungmin Hahn, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Seoul National University Bundang Hospital
name: Changsik Park, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Soonchunhyang University Hospital
name: Youngkoo Lee, MD. Ph D.
role: PRINCIPAL_INVESTIGATOR
References: